Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE®

Latest News

Stay up to date on Relief activities

Corporate News

Archive

Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011

22 May 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

15 May 2025 | non-Ad Hoc
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update

10 April 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

6 March 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

11 February 2025 | non-Ad Hoc
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

22 January 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Provides Update on Potential Transaction with Renexxion

27 December 2024 | non-Ad Hoc
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

16 December 2024 | non-Ad Hoc
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

13 December 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

11 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

4 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

29 October 2024 | non-Ad Hoc
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

25 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

21 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

8 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

18 September 2024 | non-Ad Hoc
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

2 September 2024 | non-Ad Hoc
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting

26 April 2024 | non-Ad Hoc
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

1 September 2023 | non-Ad Hoc
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health

19 July 2023 | non-Ad Hoc

Latest News

Corporate News

Archive

Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011

Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health

Company

Pipeline

Investor Relations

News and Events